

22nd May, 2026

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

**Sub.: Presentation to analysts on Audited Financial Results for the quarter and year ended
31st March, 2026**

The presentation on Audited Financial Results for the quarter and year ended 31st March, 2026 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI
COMPANY SECRETARY

TORRENT PHARMACEUTICALS LIMITED

CIN : L24230GJ1972PLC002126

Regd. Office: Avirat, Thaltej Shilaj Road, Ahmedabad – 380059

Phone: +91 79 26599000, Fax : +91 79 26582100, www.torrentpharma.com

Email – investorservices@torrentpharma.com

Revenue: Summary

Q4 FY 2025-26

Revenue: Summary

Revenues (Rs cr)	Q4 FY26	Q4 FY25	Gr%
India	2,215	1,545	43%
United States	396	302	31%
Germany	333	286	16%
Brazil	455	351	30%
Others	798	475	68%
Total	4,197	2,959	42%

Revenue: Summary

Revenues (Rs cr)	FY 26	FY 25	Gr%
India	7,645	6,393	20%
United States	1,363	1,100	24%
Germany	1,249	1,139	10%
Brazil	1,362	1,100	24%
Others	2,361	1,784	32%
Total	13,980	11,516	21%